Oct 29, 2024
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
Sep 23, 2024
Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer
Aug 01, 2024
Curis Provides Second Quarter 2024 Financial and Operating Update
Jul 25, 2024
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
Jul 10, 2024
Curis to Present at Upcoming Healthcare Conference in July
Jul 08, 2024
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 14, 2024
Curis Announces Additional Data from TakeAim Leukemia Study
May 07, 2024
Curis Provides First Quarter 2024 Business Update
Apr 30, 2024
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
Apr 05, 2024
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 08, 2024
Curis Provides Fourth Quarter 2023 Business Update
Feb 01, 2024
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
Jan 05, 2024
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 19, 2021
Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference
Feb 02, 2021
Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes
Jan 08, 2021
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 05, 2021
Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference
Dec 14, 2020
Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Dec 09, 2020
Curis Announces Pricing of Public Offering of Common Stock
Dec 08, 2020
Curis Announces Proposed Public Offering of Common Stock